Combined antiplatelet therapy in atrial fibrillation: Review of the literature and future research avenues

Journal of Cardiovascular Electrophysiology

Volumn 14, Issue 9 SUPPL., 2003, Pages

  Hohnloser, Stefan H ^a,c   Connolly, Stuart J ^b  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b MCMASTER UNIVERSITY   (Canada)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Antithrombotic therapy; Atrial fibrillation; Stroke

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; BABOON; BLEEDING; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMOSTASIS; HUMAN; ISCHEMIA; LONG TERM CARE; META ANALYSIS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; RISK; STROKE; THROMBOGENESIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0141613021     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1540-8167.14.s9.12.x     Document Type: Conference Paper

References (36)

1. Fuster V, Ryden LE: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: Executive summary. J Am Coll Cardiol 2001;38:1231-1265.
2. American Heart Association 1998: Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 1997.
3. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke. The Framingham Study. Stroke 1991;22:983-988.
4. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 1987;147:1561-1564.
5. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C for the CAFA Study Coinvestigators: Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-355.
6. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;1:175-179.
7. Stroke Prevention in Atrial Fibrillation Investigators: Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation 1991;84:527-539.
8. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-1511.
9. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, Krause-Steinrauf H, Kurtzke JF, Nazarian SM, Radford MJ, Rickles FR, Shabetai R, Deykin D, for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators: Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-1412.
10. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994;154:1449-1457.
11. EAFT (European Atrial Fibrillation Trial) Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1262.
12. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
13. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
14. Diener HC, Lowenthal A: Antiplatelet therapy to prevent stroke: Risk of brain hemorrhage and efficacy of aspirin. J Neurol Sci 1997;153:112.
15. Posada IS, Barriates V: Alternate day dosing of aspirin in atrial fibrillation. Am Heart J 1999;138:137-143.
16. Diener HC, Forbes C, Riekkinen PJ, Sivenius J, Smets P, Lowenthal A: European Stroke Prevention Study II: Efficacy and safety data. J Neurol Sci 1997;151:S27-S37.
17. Hart RG, Benavente O, McBride R, Pearce LA: Antithrornbotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis. Ann Intern Med 1999;131:492-501.
18. Hellemons BS, Langenberg M, Lodder J, et al: Primary prevention of arterial thromboembolism in patients with non-rheumatic atrial fibrillation in general practice. Cerebrovasc Dis 1997;7(Suppl 4):11.
19. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-691.
20. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Andersen ED, Godtfredsen J, Boysen G: Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation. Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-1521.
21. Taylor FC, Cohen H, Ebrahim S: Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-326.
22. Pulmonary Embolism Prevention (PEP) Trial Collaborative Group: Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;335:1295-1302.
23. Harker LA, Marzec UM, Kelly AB, Chronos NRF, Sundell IB, Hanson SR, Herbert J-M: Clopidogrel inhibition of stent, graft, and vascular thrombogenesis with antithrombotic enhancement by aspirin in nonhuman primates. Circulation 1998;98:2461-2469.
24. Bernat A, Mares AM, Defreyn G, Maffrand JP, Herbert JM: Effect of various antiplatelet agents on acute arterial thrombosis in the rat. Thromb Haemost 1993;70:812-816.
25. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE, for the Stent Anticoagulation Restenosis Study Investigators: A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-1671.
26. Bertrand ME, Legrand V, Boland J, Fleck E, Bonnier J, Emmanuelson H, Vrolix M, Missault L, Chierchia S, Casaccia M, Niccoli L, Oto A, White C, Webb-Peploe M, Van Belle E, McFadden EP: Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998;98:1597-1603.
27. Urban P, Macaya C, Rupprecht H-J, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L, for the MATTIS Investigators: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients. The Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATTIS). Circulation 1998;98:2126-2132.
28. Schomig A, Neumann F-J, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth E-M, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anti-coagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
29. Hall P, Nakamura S, Maiello L, Itoh A, Blengino S, Martini G, Ferraro M, Colombo A: A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996;93:215-222.
30. CURE Investigators: The clopidogrel in unstable angina to prevent recurrent events (CURE) programme: Rationale, design, and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease. Eur Heart J 2000;21:2033-2041.
31. Bertrand ME, Rupprecht HJ, Urban P, Gershlic AH: Double blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared to ticlopidine in combination with aspirin after coronary stenting. Circulation 2000;102:624-629.
32. Muller C, Buttner HJ, Petersen J, Roskamm H: A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after placement of coronary-artery stents. Circulation 2000;101:590-593.
33. The Clopidogrel in Unstable Angina for Prevention of Recurrent Events (CURE) Trial Investigators: Effects of clopidogrel to addition with aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502.
34. Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Topol EJ, for the CREDO Investigators: Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention. A randomized controlled trial. JAMA 2002;288:2411-2420.
35. Bungard TJ, Ghali WA, Teo KK, McAlister F, Tsuyuki RT: Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:1295-1302.
36. Howitt A, Armstrong D: Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999;318:1324-1327.